You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAzapropazone
Accession NumberDB07402
TypeSmall Molecule
GroupsWithdrawn
DescriptionNot Available
Structure
Thumb
Synonyms
Azapropazone
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
RheumoxAmdipharm Mercury Company Limited
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIK2VOT966ZI
CAS number13539-59-8
WeightAverage: 298.3397
Monoisotopic: 298.14297584
Chemical FormulaC16H18N4O2
InChI KeyInChIKey=WOIIIUDZSOLAIW-NSHDSACASA-N
InChI
InChI=1S/C16H18N4O2/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22/h5,7-9,11H,1,6H2,2-4H3/t11-/m0/s1
IUPAC Name
(4S)-7-(dimethylamino)-12-methyl-4-(prop-2-en-1-yl)-2,6,8-triazatricyclo[7.4.0.0²,⁶]trideca-1(13),7,9,11-tetraene-3,5-dione
SMILES
[H][C@@]1(CC=C)C(=O)N2N(C1=O)C1=CC(C)=CC=C1N=C2N(C)C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminotriazines. These are organic compounds containing an amino group attached to a triazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTriazines
Sub ClassAminotriazines
Direct ParentAminotriazines
Alternative Parents
Substituents
  • Aminotriazine
  • Amino-1,2,4-triazine
  • 1,2,4-triazine
  • Benzenoid
  • 1,3-dicarbonyl compound
  • Pyrazolidinone
  • Pyrazolidine
  • Tertiary amine
  • Guanidine
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9389
Caco-2 permeable+0.5728
P-glycoprotein substrateNon-substrate0.5961
P-glycoprotein inhibitor IInhibitor0.8281
P-glycoprotein inhibitor IIInhibitor0.6484
Renal organic cation transporterNon-inhibitor0.7843
CYP450 2C9 substrateNon-substrate0.8218
CYP450 2D6 substrateNon-substrate0.8107
CYP450 3A4 substrateSubstrate0.6289
CYP450 1A2 substrateInhibitor0.5528
CYP450 2C9 inhibitorNon-inhibitor0.8735
CYP450 2D6 inhibitorNon-inhibitor0.9188
CYP450 2C19 inhibitorNon-inhibitor0.8614
CYP450 3A4 inhibitorNon-inhibitor0.8273
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.725
Ames testAMES toxic0.5466
CarcinogenicityNon-carcinogens0.8321
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4784 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7311
hERG inhibition (predictor II)Non-inhibitor0.8171
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point187Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24, 1967; assigned to Siegfried AG, Switzerland Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2, 1969; assigned to Siegfried AG.
Predicted Properties
PropertyValueSource
Water Solubility0.641 mg/mLALOGPS
logP0.92ALOGPS
logP2.08ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)0.52ChemAxon
pKa (Strongest Basic)7.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area56.22 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity85.69 m3·mol-1ChemAxon
Polarizability31.94 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Molnar, I., Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,349,088; October 24,
1967; assigned to Siegfried AG, Switzerland
Molnar, I.,Wagner-Jauregg,T., Jahn, U. and Mixich, G.; US. Patent 3,482,024; December 2,
1969; assigned to Siegfried AG.

General ReferencesNot Available
External Links
ATC CodesM01AX04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabAzapropazone may increase the anticoagulant activities of Abciximab.
AcebutololAzapropazone may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Azapropazone.
AcenocoumarolAzapropazone may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Azapropazone.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Azapropazone.
Alendronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.
AliskirenAzapropazone may decrease the antihypertensive activities of Aliskiren.
AlprenololAzapropazone may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Azapropazone.
AmikacinAzapropazone may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideAzapropazone may decrease the antihypertensive activities of Amiloride.
AncrodAzapropazone may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Azapropazone.
Antithrombin III humanAzapropazone may increase the anticoagulant activities of Antithrombin III human.
ApixabanAzapropazone may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Azapropazone.
ArdeparinAzapropazone may increase the anticoagulant activities of Ardeparin.
ArgatrobanAzapropazone may increase the anticoagulant activities of Argatroban.
ArotinololAzapropazone may decrease the antihypertensive activities of Arotinolol.
AtenololAzapropazone may decrease the antihypertensive activities of Atenolol.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Azapropazone.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Azapropazone.
BalsalazideAzapropazone may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Azapropazone.
BecaplerminAzapropazone may increase the anticoagulant activities of Becaplermin.
BefunololAzapropazone may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Azapropazone.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Azapropazone.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Azapropazone.
BetaxololAzapropazone may decrease the antihypertensive activities of Betaxolol.
BevantololAzapropazone may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Azapropazone.
BisoprololAzapropazone may decrease the antihypertensive activities of Bisoprolol.
BivalirudinAzapropazone may increase the anticoagulant activities of Bivalirudin.
BopindololAzapropazone may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Azapropazone.
BufuralolAzapropazone may decrease the antihypertensive activities of Bufuralol.
BumetanideAzapropazone may decrease the diuretic activities of Bumetanide.
BupranololAzapropazone may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Azapropazone.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Azapropazone.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Azapropazone.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Azapropazone.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Azapropazone.
CarteololAzapropazone may decrease the antihypertensive activities of Carteolol.
CarvedilolAzapropazone may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Azapropazone.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Azapropazone.
CeliprololAzapropazone may decrease the antihypertensive activities of Celiprolol.
CertoparinAzapropazone may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Azapropazone.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Azapropazone.
CholestyramineCholestyramine can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Azapropazone.
Citric AcidAzapropazone may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Azapropazone.
ColesevelamColesevelam can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Azapropazone resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineAzapropazone may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Azapropazone is combined with D-Limonene.
Dabigatran etexilateAzapropazone may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinAzapropazone may increase the anticoagulant activities of Dalteparin.
DanaparoidAzapropazone may increase the anticoagulant activities of Danaparoid.
DaunorubicinAzapropazone may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Azapropazone is combined with Deferasirox.
DesirudinAzapropazone may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Azapropazone.
DextranAzapropazone may increase the anticoagulant activities of Dextran.
Dextran 40Azapropazone may increase the anticoagulant activities of Dextran 40.
Dextran 70Azapropazone may increase the anticoagulant activities of Dextran 70.
Dextran 75Azapropazone may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Azapropazone.
DicoumarolAzapropazone may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Azapropazone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Azapropazone.
DihydrostreptomycinAzapropazone may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Azapropazone.
DoxorubicinAzapropazone may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneAzapropazone may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Droxicam.
Edetic AcidAzapropazone may increase the anticoagulant activities of Edetic Acid.
EdoxabanAzapropazone may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Azapropazone.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Azapropazone.
EnoxaparinAzapropazone may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Azapropazone is combined with Epirizole.
EpirubicinAzapropazone may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneAzapropazone may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Azapropazone.
EsmololAzapropazone may decrease the antihypertensive activities of Esmolol.
Etacrynic acidAzapropazone may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Azapropazone.
Ethyl biscoumacetateAzapropazone may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Azapropazone.
EtofenamateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Azapropazone.
Evening primrose oilThe risk or severity of adverse effects can be increased when Azapropazone is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Azapropazone.
FenbufenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Azapropazone.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Azapropazone.
FlunixinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Azapropazone.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Azapropazone.
Fondaparinux sodiumAzapropazone may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Azapropazone.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Azapropazone.
FramycetinAzapropazone may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideAzapropazone may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Azapropazone.
GentamicinAzapropazone may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.
HeparinAzapropazone may increase the anticoagulant activities of Heparin.
HirulogAzapropazone may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Azapropazone.
HydralazineAzapropazone may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Azapropazone.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azapropazone.
Hygromycin BAzapropazone may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Azapropazone.
IbuproxamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Azapropazone.
IdarubicinAzapropazone may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Azapropazone.
IndenololAzapropazone may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Azapropazone.
IndoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Azapropazone.
IsoxicamThe risk or severity of adverse effects can be increased when Azapropazone is combined with Isoxicam.
KanamycinAzapropazone may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Azapropazone.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azapropazone.
LabetalolAzapropazone may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Azapropazone.
LepirudinAzapropazone may increase the anticoagulant activities of Lepirudin.
LevobunololAzapropazone may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Azapropazone.
LithiumThe serum concentration of Lithium can be increased when it is combined with Azapropazone.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Azapropazone.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Azapropazone.
LoxoprofenThe risk or severity of adverse effects can be increased when Azapropazone is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Azapropazone.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Azapropazone.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Azapropazone.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Azapropazone.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Azapropazone.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Azapropazone.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Azapropazone.
MesalazineAzapropazone may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Azapropazone.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Azapropazone.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Azapropazone.
MetipranololAzapropazone may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Azapropazone.
MetoprololAzapropazone may decrease the antihypertensive activities of Metoprolol.
MetrizamideAzapropazone may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Azapropazone.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Azapropazone.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Azapropazone.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Azapropazone.
NadololAzapropazone may decrease the antihypertensive activities of Nadolol.
NadroparinAzapropazone may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Azapropazone.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Azapropazone.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Azapropazone.
NeomycinAzapropazone may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Azapropazone.
NetilmicinAzapropazone may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Azapropazone.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Azapropazone.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Azapropazone.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.
OlsalazineAzapropazone may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Azapropazone.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Azapropazone.
OrgoteinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Orgotein.
OtamixabanAzapropazone may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Azapropazone.
OxprenololAzapropazone may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Azapropazone.
PamidronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Azapropazone is combined with Parecoxib.
ParomomycinAzapropazone may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololAzapropazone may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateAzapropazone may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azapropazone.
PhenindioneAzapropazone may increase the anticoagulant activities of Phenindione.
PhenprocoumonAzapropazone may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Azapropazone.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Azapropazone.
PindololAzapropazone may decrease the antihypertensive activities of Pindolol.
PiretanideAzapropazone may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Azapropazone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Azapropazone.
PlicamycinAzapropazone may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Azapropazone.
PractololAzapropazone may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Azapropazone.
ProbenecidThe serum concentration of Azapropazone can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Azapropazone is combined with Propacetamol.
PropranololAzapropazone may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Azapropazone.
Protein CAzapropazone may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeAzapropazone may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Azapropazone.
PuromycinAzapropazone may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Azapropazone.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Azapropazone.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Azapropazone.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Azapropazone.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Azapropazone.
ReviparinAzapropazone may increase the anticoagulant activities of Reviparin.
RibostamycinAzapropazone may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate.
RivaroxabanAzapropazone may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Azapropazone.
SalicylamideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Azapropazone.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Azapropazone.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Azapropazone.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Azapropazone.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Azapropazone.
SotalolAzapropazone may decrease the antihypertensive activities of Sotalol.
SpectinomycinAzapropazone may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Azapropazone.
SpironolactoneAzapropazone may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Azapropazone.
StreptomycinAzapropazone may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinAzapropazone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineAzapropazone may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Azapropazone.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Azapropazone.
SulodexideAzapropazone may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Azapropazone.
TacrolimusAzapropazone may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Azapropazone.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Azapropazone.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Azapropazone.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Azapropazone.
TenofovirThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Azapropazone.
TepoxalinThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Azapropazone is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Azapropazone.
TiludronateThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tiludronate.
TimololAzapropazone may decrease the antihypertensive activities of Timolol.
TobramycinAzapropazone may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Azapropazone.
TorasemideAzapropazone may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Azapropazone.
TranilastThe risk or severity of adverse effects can be increased when Azapropazone is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Azapropazone.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Azapropazone.
TriamtereneAzapropazone may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Azapropazone.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Azapropazone.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Azapropazone.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Azapropazone.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Azapropazone.
WarfarinAzapropazone may increase the anticoagulant activities of Warfarin.
XimelagatranAzapropazone may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Azapropazone.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Azapropazone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Azapropazone is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Azapropazone.
Food InteractionsNot Available

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Comments
comments powered by Disqus
Drug created on September 15, 2010 15:21 / Updated on August 17, 2016 12:24